{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:56:25Z","timestamp":1763754985529,"version":"3.45.0"},"reference-count":25,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1188\/20.cjon.392-398","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T09:49:26Z","timestamp":1594979366000},"page":"392-398","source":"Crossref","is-referenced-by-count":7,"title":["Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma"],"prefix":"10.1188","volume":"24","author":[{"given":"Maria","family":"Badillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"1","unstructured":"American Cancer Society. (2019). Benefits of good nutrition during cancer treatment. https:\/\/www.cancer.org\/treatment\/survivorship-during-and-after-treatment..."},{"key":"2","unstructured":"AstraZeneca. (2019). Calquence\u00ae (acalabrutinib) [Package insert]. https:\/\/www.azpicentral.com\/calquence\/calquence.pdf#page=1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., . . . Kaptein, A. (2017). Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. Journal of Pharmacology and Experimental Therapeutics, 363(2), 240\u2013252. https:\/\/doi.org\/10.1124\/jpet.117.242909","DOI":"10.1124\/jpet.117.242909"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Barr, P.M., Brown, J.R., Hillmen, P., O\u2019Brien, S., Barrientos, J.C., Reddy, N.M., . . . Byrd, J.C. (2017). Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL. Blood, 129(19), 2612\u20132615. https:\/\/doi.org\/10.1182\/blood-2016-12-737346","DOI":"10.1182\/blood-2016-12-737346"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cheah, C.Y., Seymour, J.F., & Wang, M.L. (2016). Mantle cell lymphoma. Journal of Clinical Oncology, 34(11), 1256\u20131269. https:\/\/doi.org\/10.1200\/JCO.2015.63.5904","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E., & Lister, T.A. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. Journal of Clinical Oncology, 32(27), 3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Cohen, J.B., Zain, J.M., & Kahl, B.S. (2017). Current approaches to mantle cell lymphoma: Diagnosis, prognosis, and therapies. American Society of Clinical Oncology Educational Book, 37, 512\u2013525. https:\/\/doi.org\/10.14694\/EDBK_175448","DOI":"10.14694\/EDBK_175448"},{"key":"8","doi-asserted-by":"crossref","unstructured":"de Almeida, M.H., Pagnano, K.B.B., Vigorito, A.C., Lorand-Metze, I., & de Souza, C.A. (2013). Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A Brazilian single-center cohort. Acta Haematologica, 130(1), 16\u201322. https:\/\/doi.org\/10.1159\/000345722","DOI":"10.1159\/000345722"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Henk, H.J., Woloj, M., Shapiro, M., & Whiteley, J. (2015). Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clinical Therapeutics, 37(1), 124\u2013133. https:\/\/doi.org\/10.1016\/j.clinthera.2014.10.019","DOI":"10.1016\/j.clinthera.2014.10.019"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H.C.,. . . Unterhalt, M. (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111(2), 558\u2013565. https:\/\/doi.org\/10.1182\/blood-2007-06-095331","DOI":"10.1182\/blood-2007-06-095331"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kaptein, A., de Bruin, G., Emmelot-van Hoek, M., van der Kar, B., de Jong, A., Gulrajani, M., . . . Barf, T. (2018). Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood, 132(Suppl. 1), 1871. https:\/\/doi.org\/10.1182\/blood-2018-99-109973","DOI":"10.1182\/blood-2018-99-109973"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., . . . Khorashad, J.S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381\u20132388. https:\/\/doi.org\/10.1200\/JCO.2009.26.3087","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Mato, A.R., Nabhan, C., Thompson, M.C., Lamanna, N., Brander, D.M., Hill, B., . . . Ujjani, C.S. (2018). Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis. Haematologica, 103(5), 874\u2013879. https:\/\/doi.org\/10.3324\/haematol.2017.182907","DOI":"10.3324\/haematol.2017.182907"},{"key":"14","unstructured":"National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events (CTCAE) [v.4.03]. U.S. Department of Health and Human Services. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReferen..."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zach\u00e9e, P., Berneman, Z., . . . Abraham, I. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood, 113(22), 5401\u20135411. https:\/\/doi.org\/10.1182\/blood-2008-12-196543","DOI":"10.1182\/blood-2008-12-196543"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Non-Hodgkin\u2019s Lymphoma Classification Project. (1997). A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood, 89(11), 3909\u20133918. https:\/\/doi.org\/10.1182\/blood.V89.11.3909","DOI":"10.1182\/blood.V89.11.3909"},{"key":"17","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, S., Furman, R.R., Coutre, S., Flinn, I.W., Burger, J.A., Blum, K., . . . Byrd, J.C. (2018). Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: A 5-year experience. Blood, 131(17), 1910\u20131919. https:\/\/doi.org\/10.1182\/blood-2017-10-810044","DOI":"10.1182\/blood-2017-10-810044"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Partridge, A.H., Avorn, J., Wang, P.S., & Winer, E.P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94(9), 652\u2013661. https:\/\/doi.org\/10.1093\/jnci\/94.9.652","DOI":"10.1093\/jnci\/94.9.652"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ponader, S., & Burger, J.A. (2014). Bruton\u2019s tyrosine kinase: From X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. Journal of Clinical Oncology, 32(17), 1830\u20131839. https:\/\/doi.org\/10.1200\/JCO.2013.53.1046","DOI":"10.1200\/JCO.2013.53.1046"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Ruddy, K., Mayer, E., & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59(1), 56\u201366. https:\/\/doi.org\/10.3322\/caac.20004","DOI":"10.3322\/caac.20004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Vose, J.M. (2017). Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. American Journal of Hematology, 92(8), 806\u2013813. https:\/\/doi.org\/10.1002\/ajh.24797","DOI":"10.1002\/ajh.24797"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., . . . Blum, K.A. (2013). Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369(6), 507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","DOI":"10.1056\/NEJMoa1306220"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Wang, M., Rule, S., Zinzani, P.L., Goy, A., Casasnovas, O., Smith, S.D., . . . D\u0142ugosz-Danecka, M. (2019). Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia, 33(11), 2762\u20132766. https:\/\/doi.org\/10.1038\/s41375-019-0575-9","DOI":"10.1038\/s41375-019-0575-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Wang, M., Rule, S., Zinzani, P.L., Goy, A., Casasnovas, O., Smith, S.D., . . . Jurczak, W. (2018). Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet, 391(10121), 659\u2013667. https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Wang, H., Fang, W., Romaguer, J.E., Zhang, Y., Delasalle, K.B., . . . Wang, M. (2008). Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer, 113(4), 791\u2013798. https:\/\/doi.org\/10.1002\/cncr.23608","DOI":"10.1002\/cncr.23608"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/24\/4\/acalabrutinib-managing-adverse-events-and-improving-adherence-patients-mantle-cell","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:15Z","timestamp":1763754615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/24\/4\/acalabrutinib-managing-adverse-events-and-improving-adherence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1188\/20.cjon.392-398","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}